NCT06418802

Brief Summary

Objectives: Parkinson's disease (PD) is the second most common degenerative disease of the nervous system. Postural instability/gait disorder (PIGD) is one of the motor symptoms of Parkinson's disease, which affects the quality of life of patients with Parkinson's disease. At present, deep brain stimulation(DBS)can significantly improve tremor and bradykinesia, but whether deep brain stimulation is effective for gait disorders is still a controversial topic. In addition, the previous gait assessment mainly focused on scales or simple walking tests, and appropriate and effective evaluation methods are needed to evaluate the efficacy of intervention for gait disorders in PD patients. Therefore, in view of these problems, this study will use wearable devices and traditional scale evaluation to explore the effects of deep brain stimulation on gait in patients with Parkinson's disease. Methods: A total of 30 patients with Subthalamic nucleus DBS(STN-DBS)were expected to be enrolled. By adjusting the parameters of STN-DBS (voltage, frequency, pulse width), the effects of different parameters on PD gait were compared. Gait changes were mainly analyzed by wearable devices and MDS Unified Parkinson's Disease Rating Scale assessment(MDS-UPDRS). The (Timed Up and Go)TUG test, narrow channel task, circle task and trajectory analysis were performed in the unmedicated state. The wearable device was used to collect the motion information of 10 different positions of the human body, including the wrist, thigh, ankle, foot tip, chest and waist nodes. (1)Experiment 1: Patients were divided into pre-operation group and post-operation group. A case-control study was conducted, and patients were followed up at 1 month,3 months,6 months and 1 year after operation. (2)Experiment 2: This study was a single-center, randomized, double-blind, crossover trial of deep brain stimulation with a short pulse width (30s) versus conventional pulse width (60 s) in PD patients with bilateral STN-DBS. Gait data and MDS-UPDRS were collected at baseline, after 4 weeks and 8 weeks. (3)Experiment 3: By adjusting the frequency parameters of STN-DBS (30,100, and 130HZ), gait data and MDS-UPDRS were collected after 10 minutes of the washout period, and the best DBS parameters for gait improvement were maintained for 4-8 weeks and then evaluated again. Expected results: By adjusting the parameters (voltage, frequency, and pulse width) of STN-DBS, the potential mechanisms for improving gait disorders in PD were explored, meaningful digital biomarkers for PD gait prognosis were explored, and long-term programming of STN-DBS was guided.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for not_applicable parkinson-disease

Timeline
Completed

Started Jun 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 14, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 17, 2024

Completed
15 days until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

May 17, 2024

Status Verified

March 1, 2024

Enrollment Period

1.5 years

First QC Date

May 14, 2024

Last Update Submit

May 14, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Gait data

    Gait changes were analyzed by wearable devices and MDS-UPDRS.

    Pre-operation(baseline),1 month,3 months,6 months and 1 year after operation.

  • Gait data

    Gait changes were analyzed by wearable devices and MDS-UPDRS.

    Baseline, after 4 weeks and 8 weeks.

  • Gait data

    Gait changes were analyzed by wearable devices and MDS-UPDRS.

    Baseline, after 10 minutes of the washout period, after4-8 weeks.

Study Arms (6)

Experiment 1: Experimental group 1

EXPERIMENTAL

PD Patient's gait were followed up at 1 month,3 months,6 months, and 1 year after bilateral STN-DBS surgery.

Procedure: STN-DBS surgery

Experiment 1: Comparator group 1

ACTIVE COMPARATOR

PD patient's gait with optimal medical therapy before bilateral STN-DBS surgery.

Procedure: STN-DBS surgery

Experiment 2: Experimental group 2

EXPERIMENTAL

PD patient's gait with a short pulse width (30s) with bilateral STN-DBS.

Device: pulse width

Experiment 2: Comparator group 2

ACTIVE COMPARATOR

PD patient's gait with the conventional pulse width (60 s) with bilateral STN-DBS.

Device: pulse width

Experiment 3: Experimental group 3

EXPERIMENTAL

PD patient's gait with frequency parameters(60,100, and 130HZ) with bilateral STN-DBS.

Device: frequency

Experiment 3: Comparator group 3

ACTIVE COMPARATOR

PD patient's gait with the conventional frequency parameters with bilateral STN-DBS.

Device: frequency

Interventions

bilateral subthalamic nucleus deep brain stimulation surgery

Experiment 1: Comparator group 1Experiment 1: Experimental group 1

a short pulse width (30s)

Experiment 2: Comparator group 2Experiment 2: Experimental group 2
frequencyDEVICE

frequency parameters of STN-DBS (60,100, and 130HZ)

Experiment 3: Comparator group 3Experiment 3: Experimental group 3

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • (1) Age 40-75 years old; (2) Patients who meet the Chinese Parkinson's disease diagnostic criteria and confirmed by two high-level physicians (\>10 years); (3) Diagnosed by Parkinson's Specialty Clinic For Parkinson's disease for more than 1 year and have been effective after treatment; (4) Hearing, visual and cognitive abilities are normal; (5) The subjects were informed of the test purpose, the benefits of the test, the test process and possible unexpected situations before the test , and signed the trial informed consent form.

You may not qualify if:

  • (1) A variety of secondary Parkinson's syndrome (including traumatic, drug-induced, tumor, vascular, toxic, hydrocephalus, etc.) and Parkinson's superimposed syndrome. (2) Other diseases that cause gait disorders, including spinal joint injuries, muscle spasm, stroke, peripheral neuropathy, muscle diseases, hydrocephalus, cognitive impairment, etc. (3) Accompanied by vital organ (heart, lung, liver, kidney, etc.) failure, malignant tumors, unstable conditions and other serious medical diseases. (4) Those who have serious behavior problems or mental confusion. (5)Those who do not cooperate with the examination.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 14, 2024

First Posted

May 17, 2024

Study Start

June 1, 2024

Primary Completion

December 1, 2025

Study Completion

March 1, 2026

Last Updated

May 17, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share